BiotechTube

Etripamil + Placebo + Etripamil Test Dose

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Paroxysmal Supraventricular Tachycardia

Conditions

Paroxysmal Supraventricular Tachycardia

Trial Timeline

Jun 18, 2018 → Jan 20, 2023

NCT ID
NCT03464019

About Etripamil + Placebo + Etripamil Test Dose

Etripamil + Placebo + Etripamil Test Dose is a phase 3 stage product being developed by Medpace for Paroxysmal Supraventricular Tachycardia. The current trial status is terminated. This product is registered under clinical trial identifier NCT03464019. Target conditions include Paroxysmal Supraventricular Tachycardia.

What happened to similar drugs?

0 of 20 similar drugs in Paroxysmal Supraventricular Tachycardia were approved

Approved (0) Terminated (3) Active (17)
🔄Crovalimab + EculizumabChugai PharmaceuticalPhase 3
🔄Crovalimab + EculizumabChugai PharmaceuticalPhase 3
🔄EculizumabAstraZenecaPhase 3
🔄DanicopanAstraZenecaPhase 3
🔄Iptacopan (LNP023)NovartisPhase 3
🔄IptacopanNovartisPhase 3
🔄LNP023 + Eculizumab + RavulizumabNovartisPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03464019Phase 3Terminated

Competing Products

20 competing products in Paroxysmal Supraventricular Tachycardia

See all competitors
ProductCompanyStageHype Score
Crovalimab + EculizumabChugai PharmaceuticalPhase 3
44
Crovalimab + PlaceboChugai PharmaceuticalPhase 1/2
36
Crovalimab + EculizumabChugai PharmaceuticalPhase 3
44
RavulizumabAstraZenecaPre-clinical
30
EculizumabAstraZenecaPhase 3
40
DanicopanAstraZenecaPhase 3
47
LNP023NovartisPre-clinical
33
Iptacopan (LNP023)NovartisPhase 3
40
iptacopanNovartisPhase 2
35
LNP023NovartisPhase 2
35
IptacopanNovartisPre-clinical
30
IptacopanNovartisPhase 3
40
LNP023 + Eculizumab + RavulizumabNovartisPhase 3
40
LNP023NovartisPhase 3
47
LFG316 + LNP023NovartisPhase 2
35
IptacopanNovartisPhase 3
44
CrovalimabRochePhase 3
44
ABP 959 + EculizumabAmgenPhase 3
40
PegcetacoplanSwedish Orphan BiovitrumPre-clinical
33
BMS-919373 + Placebo (Matching with BMS-919373)Bristol Myers SquibbPhase 2
27